AMPH Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -255.85%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $32.33, signalling upside risk potential of 17.86%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.04x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.85x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of --. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Palatin Technologies's return on equity of --.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $32.33, signalling upside risk potential of 17.86%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Amphastar Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than Palatin Technologies quarterly revenues of --. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Palatin Technologies's net income of --. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.04x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.85x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -23.49%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $32.33, signalling upside risk potential of 17.86%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $60.50 which suggests that it could grow by 35.17%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.462%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.04x while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.85x versus 3.70x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of --. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $32.33, signalling upside risk potential of 17.86%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.04x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.85x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.